IART Integra Lifesciences Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IART

Price (delayed)

$18

Market cap

$1.4B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$3.23B

?
Relative Growth: Rel. Growth: 57
Relative Strength: Rel. Strength: 89
Relative Valuation: Rel. Valuation: 49
Relative Profitability: Rel. Profitability: 54

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative ...

Highlights
IART's quick ratio has soared by 183% YoY and by 7% from the previous quarter
IART's EPS has surged by 99% year-on-year and by 99% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.integralife.com
Peers: SYK TFX XRAY CNMD

Key stats

What are the main financial stats of IART

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
8.11%
1 week
-7.83%
1 month
-0.28%
1 year
46.22%
YTD
44.93%
QTD
0.22%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.65B
Gross profit
$864.58M
Operating income
$65.56M
Net income
-$7.24M
Gross margin
52.5%
Net margin
-0.4%
The operating income has surged by 114% since the previous quarter and by 113% year-on-year
IART's operating margin has soared by 114% since the previous quarter and by 113% year-on-year
The net margin has soared by 99% year-on-year and by 99% since the previous quarter
Integra Lifesciences Holdings's net income has soared by 99% YoY and by 99% from the previous quarter

Price vs fundamentals

How does IART's price correlate with its fundamentals

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
IART P/E details
P/E
N/A
P/B
1.34
P/S
0.84
EV/EBIT
35.28
EV/EBITDA
13.21
EV/Sales
1.96
IART's EPS has surged by 99% year-on-year and by 99% since the previous quarter
The P/B is 35% lower than the 5-year quarterly average of 1.9 but 24% higher than the last 4 quarters average of 1.0
The price to sales (P/S) is 59% less than the 5-year quarterly average of 1.9 but 30% more than the last 4 quarters average of 0.6

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's return on sales has surged by 121% since the previous quarter and by 119% year-on-year
IART's return on invested capital has surged by 120% since the previous quarter and by 115% year-on-year
Integra Lifesciences Holdings's return on equity has surged by 99% QoQ and by 98% YoY
IART's ROA has soared by 99% QoQ and by 98% YoY

Dividends

What is IART's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 41% higher than its total liabilities
The current ratio has soared by 193% year-on-year and by 7% since the previous quarter
IART's quick ratio has soared by 183% YoY and by 7% from the previous quarter
The debt is 96% greater than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.